Men over 40 of age were encouraged to take Prostate-specific antigen (PSA) and other tests, an important step in both identifying prostate cancer earlier and in understanding one’s risk profile. Research shows that when detected early the survival rate for men with prostate cancer is 98%, dropping to 29% when detected at later stages.
Commenting on the event, Michelle Akande, Country Manager, Janssen Pharmaceutical Companies of Johnson & Johnson said, “Johnson & Johnson has been responding to healthcare needs for 125 years and our ambition is to change the trajectory of health for humanity in Nigeria. Today, we are proud to be partnering with mDoc, Project PINK BLUE, and The American Business Council to change the trajectory of prostate cancer in Nigeria. Overwhelmingly, late presentation to the healthcare system and poor outcomes characterize the prostate cancer experience of men in Nigeria today. Yet evidence tells us that early detection and lifestyle modifications can both improve outcomes for those with prostate cancer and reduce the associated risk factors of prostate cancer. It is very important that we increase our individual and collective understanding of prostate cancer.”
She said, “Time For Life is adding to the national conversation about prostate cancer and is in support of the Federal Ministry of Health’s National Cancer Control Plan 2018 – 2022, which sets out ambitious goals, including: of making screening services and early detection of cancer available for all Nigerians, as well as increasing cancer awareness amongst the population.”